Please ensure Javascript is enabled for purposes of website accessibility

BioFactura gets federal contract to develop smallpox drug

A Frederick maker of biodefense countermeasures has received a contract worth up to $67.4 million for development of a smallpox drug.

BioFactura Inc. was awarded the contract by the Biomedical Advanced Research and Development Authority for advanced development of its Smallpox biodefense therapeutic.

The base phase of the contract is worth $9.5 million. During the base phase, work will focus on the development of manufacturing processes for the drug components, final product formulation, analytical method development, stability studies and activities to support engagement with the FDA.

The contract also has three option phases that may be activated to support process optimization and clinical manufacturing and additional non-clinical development studies.

Dr. Darryl Sampey, president and CEO of BioFactura, said in a news release that the award is the culmination of decades of work at BioFactura, the National Institutes of Health and the U.S. Army Research Institute of Infectious Diseases.

To purchase a reprint of this article, contact [email protected].